{"id":3724,"date":"2026-10-14T09:00:00","date_gmt":"2026-10-14T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=3724"},"modified":"2026-10-14T22:08:53","modified_gmt":"2026-10-15T02:08:53","slug":"srp-1003-shows-nuclear-dmpk-rna-knockdown","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=3724","title":{"rendered":"SRP-1003 Shows Nuclear DMPK RNA Knockdown"},"content":{"rendered":"

\"\"<\/p>\n

Company<\/strong><\/p>\n

Sarepta Therapeutics<\/p>\n

Event Type<\/strong><\/p>\n

Preclinical Data Presentation (Oligonucleotide Therapeutics Society)<\/p>\n

Modality<\/strong><\/p>\n

siRNA; alpha-v-beta-6 integrin-targeted muscle delivery<\/p>\n

Asset<\/strong><\/p>\n

SRP-1003<\/p>\n

Target<\/strong><\/p>\n

DMPK RNA (nuclear and cytoplasmic)<\/p>\n

Disease Area<\/strong><\/p>\n

Myotonic dystrophy type 1 (DM1)<\/p>\n

Summary<\/h4>\n

Sarepta presented new preclinical data showing that its alpha-v-beta-6 integrin-targeted siRNA SRP-1003 reduced pathogenic DMPK RNA in both nuclear and cytoplasmic compartments of DM1 patient-derived myotubes, reaching approximately 80% knockdown in each. Independent assays also showed fewer nuclear RNA foci and correction of MBNL-dependent mis-splicing in model systems.<\/p>\n

The work strengthens the mechanistic case that a systemically delivered siRNA can access the nuclear toxic-RNA pool central to myotonic dystrophy type 1. The data are preclinical and do not establish human nuclear target engagement, clinical benefit, chronic safety, or superiority to competing oligonucleotide approaches.<\/p>\n

At the Oligonucleotide Therapeutics Society meeting, Sarepta reported compartment-fractionated ddPCR, RNA FISH, and RNAscope evidence of nuclear engagement. In DMSXL mice, treatment reduced nuclear foci in skeletal muscle, diaphragm, and myocardium.<\/p>\n

In a second mouse model expressing pathogenic human DMPK, a surrogate siRNA reduced nuclear RNA and corrected dose-dependent MBNL-related mis-splicing by RNA sequencing. Separate preclinical studies detected SRP-1003 across multiple muscle groups up to 16 weeks after one intravenous dose.<\/p>\n

SRP-1003 is already in a randomized, placebo-controlled Phase 1\/2 single- and multiple-ascending-dose study in adults with DM1. The October presentation is a mechanistic preclinical update, not a new clinical efficacy readout.<\/p>\n

Deep Analysis<\/h4>\n

Disease and mechanism.<\/strong> DM1 is caused by expanded CTG repeats in DMPK. Toxic CUG-repeat RNA accumulates in the nucleus, sequesters MBNL proteins, and disrupts splicing across many transcripts. A therapy must reach skeletal, cardiac, respiratory, and potentially smooth muscle and reduce the nuclear RNA pool sufficiently to restore downstream RNA processing.<\/p>\n

Delivery.<\/strong> Sarepta’s platform uses alpha-v-beta-6 integrin targeting to deliver siRNA to muscle. The reported nuclear activity addresses a central objection to RNAi against retained nuclear transcripts. However, receptor expression can vary by muscle, disease stage, regeneration, and organ, and mouse or myotube distribution does not establish human tissue coverage.<\/p>\n

Safety and durability.<\/strong> Sixteen-week tissue detectability supports infrequent dosing but is not equivalent to sustained RISC activity or clinical effect. Development must assess immune activation, complement, liver and kidney effects, thrombocytopenia, cardiac conduction, respiratory function, anti-drug responses, and reversibility after repeat dosing.<\/p>\n

Competitive context.<\/strong> DM1 programs include antisense oligonucleotides, RNAi, small molecules, and gene-editing concepts. SRP-1003 could differentiate through systemic muscle delivery and nuclear knockdown, but clinical displacement requires consistent biopsy pharmacodynamics across muscles, splicing correction, functional benefit, and a tolerable chronic dose.<\/p>\n

Company and Product Background<\/h4>\n

Sarepta develops precision genetic medicines and is applying targeted siRNA delivery to muscle diseases. SRP-1003 is its DM1 candidate; the company has previously reported early clinical platform data, but today’s disclosure is preclinical.<\/p>\n

DM1 is a multisystem disorder affecting skeletal muscle, heart, respiration, endocrine function, and other organs. There is no approved disease-modifying therapy, raising the value of approaches that reach distributed tissues.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • Verified facts:<\/strong> up to approximately 80% DMPK knockdown in nuclear and cytoplasmic fractions of patient-derived myotubes; confirmation by three assay classes; reduced foci and mis-splicing correction in models; tissue detectability up to 16 weeks in preclinical studies.<\/li>\n
  • Company claims:<\/strong> these data support continued clinical advancement and demonstrate effective nuclear entry. The assays support nuclear mechanism in models, not human clinical effect.<\/li>\n
  • Missing facts:<\/strong> human biopsy data, receptor-expression variability, exact dose margins, repeat-dose toxicology, unbiased off-target transcript effects, cardiac and CNS distribution, clinical splicing correction, and functional outcomes.<\/li>\n
  • Interpretation one:<\/strong> the study resolves a key mechanistic risk by showing nuclear pathogenic-RNA degradation. Orthogonal assays and downstream splicing rescue support this. Model-to-human delivery remains the main contradiction.<\/li>\n
  • Interpretation two:<\/strong> the observed nuclear effect may not be reproducible across human muscles at a safe systemic dose. Tissue heterogeneity and chronic exposure support this concern. The ongoing randomized clinical study can directly test it.<\/li>\n<\/ul>\n

    InSilens Take<\/h4>\n

    Insilens inference: the update is valuable because it links compartment-level knockdown to a functional RNA-processing consequence. It should be viewed as mechanistic bridge evidence while waiting for human biopsy and splicing data.<\/p>\n

    The thesis would be upgraded by dose-dependent human muscle DMPK knockdown, MBNL-splicing correction, broad tissue coverage, and clean repeat-dose safety. It would be downgraded by variable receptor expression, discordant biopsy results, or biomarker change without function. It would be falsified if adequate systemic exposure fails to reduce nuclear DMPK safely in patients.<\/p>\n

    Signal Assessment<\/h4>\n

    Signal Importance: 4 of 5. Signal Direction: Positive for mechanism validation; uncertain for clinical translation. Confidence in Facts: High. Confidence in Interpretation: Moderate. Red-team result: preclinical nuclear knockdown is not presented as human efficacy or treatment readiness.<\/p>\n","protected":false},"excerpt":{"rendered":"

    Sarepta presented new preclinical data showing that its alpha-v-beta-6 integrin-targeted siRNA SRP-1003 reduced pathogenic DMPK RNA in both nuclear and cytoplasmic compartments of DM1 patient-derived myotubes, reaching approximately 80% knockdown in each. Independent assays…<\/p>\n","protected":false},"author":1,"featured_media":3727,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[618,698,616,207,866],"class_list":["post-3724","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-technology-modalities","tag-dmpk","tag-integrin","tag-myotonic-dystrophy-type-1","tag-sarepta-therapeutics","tag-sirna"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3724","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3724"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3724\/revisions"}],"predecessor-version":[{"id":3738,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3724\/revisions\/3738"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3727"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3724"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3724"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3724"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}